Purpose: India has high rates of cardiovascular diseases (CVD). Yet there are no representative data on the barriers and strategies to improve CVD care in India. We aimed to analyse the barriers and elicit strategies, which are important to implement programs and policies. Methods: We conducted a nationwide cross-sectional study among physicians at randomly selected hospitals, stratified by region, population and level of health care. Sample size for hospitals was based on community prevalence of CVD. At each hospital we randomly selected an average of 10 physicians. All self reported questionnaires were anonymously collected between March 2012 and January 2013. The questions included description of physicians, patients seen, risk factors, barriers perceived and strategies suggested to manage CVD. Results: We received completed questionnaires from 1,271 physicians (from 124 hospitals at 75 cities in 22 states that represent 94.1% of the population). Physicians were internists (54.3%), specialists (27.7%) and generalists (18.0%). The median years since qualification were 7 (inter quartile range 3.0 -16.0) and they practiced for 8.4 (± 3.01) hours a day. Most (70%) used international guidelines for management. The stated barriers for optimal CVD management were cost and access to medication (92.0%), literacy (86.9%), complex regimen (86.1%), lack of family support (79.0%), poor follow up (75.0%), lack of adequate hospital staff (56.6%), complementary and alternative medication (50.0%) and high patient load (49.9%). Strategies suggested to improve CVD management were related to practice (use non physicians 90.4%, additional medical staff 88.6%), patients (more education 93.4%, provide written material 83.6%, mobile text reminder 52.0%), physicians (better access to guidelines and updates 95.3%, compulsory CME 87.0%, better internet access 85.1%, clinical research participation 79.8%) and policy (better infrastructure 94.0%, hospital registries 93.3%, IT infrastructure 88.5%, Government subsidy for treatments 87.5%, universal health insurance 83.3%). Conclusions: This first nationwide survey identified significant barriers and elicited practical strategies for better CVD care. The Government and health care providers must urgently consider these findings to implement policies and programs to reduce the high CVD mortality in India. Background: The prevalence of asymptomatic carotid plaque (a-CP) is high in patients with inflammatory joint disease (IJD). Patients with a-CP should receive intensive lipid lowering treatment (LLT) in cardiovascular (CV)prevention. Our aim was to evaluate presence of a-CP, if CV risk calculators predict presence of a-CP in IJD patients and if optimizing cut off points in risk calculators will improve this prediction. Methods: We performed CV risk stratification in IJD patients (n= 345) by using SCORE CV risk algorithms with recommended cut off points at 5%, 10% and 10% respectively. Ultrasound of the carotid arteries was performed. Cross-tabulations, Chi2 and ROC curves were used to calculate sensitivity/specificity, odds-and likelihood ratio (LR) for identifying a-CP. The ROC closest point (0.1) and 80% sensitivity was used for optimizing the identification of a-CP. Results: Two hundred and eleven patients had SCORE<5% indicating no need for LL prevention (Table) . However, 72 (34.1%) of these patients had a-CP and should receive intensive LLT. In patients with SCORE >5% (n=124), indicating a need for moderate LL prevention, 81 (65.3%) had a-CP and should therefore receive intensive LLT. The sensitivity for identifying a-CP was 0.53, the specificity: 0.76 and LR+: 2.24. Optimizing the cut off value by using closest point (0, 1) (SCORE: 4%: specificity: 0.65, specificity: 0.72, LR+:2.33) or 80% specificity (SCORE: 2.65: sensitivity: 0.80 specificity: 0.56 LR+:1.83) did not improve the
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Impact of asymptomatic atherosclerosis on CV prevention in patients with rheumatic joint diseases
Background: The prevalence of asymptomatic carotid plaque (a-CP) is high in patients with inflammatory joint disease (IJD). Patients with a-CP should receive intensive lipid lowering treatment (LLT) in cardiovascular (CV)prevention. Our aim was to evaluate presence of a-CP, if CV risk calculators predict presence of a-CP in IJD patients and if optimizing cut off points in risk calculators will improve this prediction. Methods: We performed CV risk stratification in IJD patients (n= 345) by using SCORE CV risk algorithms with recommended cut off points at 5%, 10% and 10% respectively. Ultrasound of the carotid arteries was performed. Cross-tabulations, Chi2 and ROC curves were used to calculate sensitivity/specificity, odds-and likelihood ratio (LR) for identifying a-CP. The ROC closest point (0.1) and 80% sensitivity was used for optimizing the identification of a-CP. Results: Two hundred and eleven patients had SCORE<5% indicating no need for LL prevention (Table) . However, 72 (34.1%) of these patients had a-CP and should receive intensive LLT. In patients with SCORE >5% (n=124), indicating a need for moderate LL prevention, 81 (65.3%) had a-CP and should therefore receive intensive LLT. The sensitivity for identifying a-CP was 0.53, the specificity: 0.76 and LR+: 2.24. Optimizing the cut off value by using closest point (0, 1) (SCORE: 4%: specificity: 0.65, specificity: 0.72, LR+:2.33) or 80% specificity (SCORE: 2.65: sensitivity: 0.80 specificity: 0.56 LR+:1.83) did not improve the SCORE and presence of carotid plaques ability of SCORE to identify a-CP. CP was not adequately identifyed applying the updated SCORE (2011). Conclusion: Carotid ultrasound will reclassify patients with IJD into correct intensive LLT in about 1/3 of patients with SCORE<5% and 2/3 of patients with SCORE>5%. This has important clinical implications.
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Use of analgesics and risk of death after discharge from elective hip or knee replacement -a nationwide cohort study A.M. Schjerning Olsen, G. Gislason, C. Torp-Pedersen, C. Andersson. Department of Cardiology, Copenhagen University Hospital,Gentofte, Denmark, Hellerup, Denmark Purpose: Individual drugs for pain management may have different risk profile, especially among elderly individuals. We investigated the risk of mortality with use of analgesics during the first six months after discharge from elective hip or knee replacement surgery. Methods: Through cross-linkage of Danish nationwide administrative registers, we identified patients discharged alive after elective hip or knee replacement between mid 2004 and end 2009. Risk of mortality during the first six months associated with use of diclofenac, ibuprofen, naproxen, tramadol, and morphine was analyzed by multivariable time-dependent Cox proportional hazard regression. Results: In total 28,467 patients were included (60% women and mean age 69.0 (inter quartile range 61.6-76.5) years) of which 15,573 (55%) had a total hip replacement. A total of 2,459 patients received diclofenac, 7,044 ibuprofen, 379 naproxen, 9,851 tramadol, 11,696 paracetamol, and 6,679 morphine. During follow-up 380 patients died (21 in diclofenac, 37 in ibuprofen, 2 in naproxen, 80 in tramadol, 206 in paracetamol, and 87 in morphine treatment). The adjusted Cox regression analysis demonstrated that morphine and diclofenac were associated with increased mortality (Figure) while ibuprofen, naproxen, tramadol and paracetamol were not associated with increased risk. Conclusions: Treatment with diclofenac or morphine during the first six months after discharge from elective hip or knee replacement was associated with increased mortality-risk. Awareness on potential risk of adverse events associated with these drugs after hip-or knee-replacement surgery is warranted.
